Ethical issues in stem cell research and therapy

Abstract

Rapid progress in biotechnology has introduced a host of pressing ethical and policy issues pertaining to stem cell research. In this review, we provide an overview of the most significant issues with which the stem cell research community should be familiar. We draw on a sample of the bioethics and scientific literatures to address issues that are specific to stem cell research and therapy, as well as issues that are important for stem cell research and therapy but also for translational research in related fields, and issues that apply to all clinical research and therapy. Although debate about the moral status of the embryo in human embryonic stem cell research continues to have relevance, the discovery of other highly multipotent stem cell types and alternative methods of isolating and creating highly multipotent stem cells has raised new questions and concerns. Induced pluripotent stem cells hold great promise, but care is needed to ensure their safety in translational clinical trials, despite the temptation to move quickly from bench to bedside. A variety of highly multipotent stem cells - such as mesenchymal stem/stromal cells and stem cells derived from amniotic fluid, umbilical cord blood, adipose tissue, or urine - present the opportunity for widespread biobanking and increased access. With these increased opportunities, however, come pressing policy issues of consent, control, and justice. The imperatives to minimize risks of harm, obtain informed consent, reduce the likelihood of the therapeutic misconception, and facilitate sound translation from bench to bedside are not unique to stem cell research; their application to stem cell research and therapy nonetheless merits particular attention. Because stem cell research is both scientifically promising and ethically challenging, both the application of existing ethical frameworks and careful consideration of new ethical implications are necessary as this broad and diverse field moves forward.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 53

1. 1.

   Lo B Parham L Resolving ethical issues in stem cell clinical trials: the example of Parkinson diseaseJ Law Med Ethics2010 38257266

   Not in our library10.1111/j.1748-720x.2010.00486.x

2. 2.

   Habets MG van Delden JJ Bredenoord AL The inherent ethical challenge of first-in-human pluripotent stem cell trialsRegen Med2014 913

   Not in our library10.2217/rme.13.83

3. 3.

   Niemansburg SL Teraa M Hesam H van Delden JJ Verhaar MC Bredenoord AL Stem cell trials for cardiovascular medicine: ethical rationaleTiss Eng Part A2013 [Epub ahead of print]

   Not in our library10.1089/ten.tea.2013.0332

4. 4.

   Levine R Ethics and Regulation of Clinical Research1988 New York: Yale University Press

   Not in our library

5. 5.

   Gilbert S Kaebnick GE Murray TH Special Report: Animal research ethics: evolving views and practicesHastings Center Rep2012 42S1S39

   Not in our library

6. 6.

   Joffe S Miller FG Bench to bedside: mapping the moral terrain of clinical researchHastings Center Rep2008 383042

   Not in our library10.1353/hcr.2008.0019

7. 7.

   Arcidiacono JA Blair JW Benton KA US Food and Drug Administration international collaborations for cellular therapy product regulationStem Cell Res Ther2012 33842

   Not in our library10.1186/scrt129

8. 8.

   Caulfield T Zarzeczny A McCormick J Bubela T Critchley C Einsiedel E Galipeau J Harmon S Huynh M Hyun I Illes J Isasi R Joly Y Laurie G Lomax G Longstaff H McDonald M Murdoch C Ogbogu U Owen-Smith J Pattinson S Premji S von Tigerstrom B Winickoff DE The stem cell research environment: a patchwork of patchworksStem Cell Rev2009 58288

   Not in our library10.1007/s12015-009-9071-3

9. 9.

   Greely H Assessing ESCROs: yesterday and tomorrowAm J Bioeth2013 134452

   Not in our library10.1080/15265161.2013.747340

10. 10.

    Lomax GP Peckman SR Stem cell policy exceptionalism: proceed with cautionStem Cell Rev Rep2012 8299304

    Not in our library10.1007/s12015-011-9305-z

11. 11.

    Hyun I Lindvall O Ahrlund-Richter L Cattaneo E Cavazzana-Calvo M Cossu G De Luca M Fox IJ Gerstle C Goldstein RA Hermeren G High KA Kim HO Lee HP Levy-Lahad E Li L Lo B Marshak DR McNab A Munsie M Nakauchi H Rao M Rooke HM Valles CS Srivastava A Sugarman J Taylor PL Veiga A Wong AL Zoloth L Daley GQ New ISSCR guidelines underscore major principles for responsible translational stem cell researchCell Stem Cell2008 3607609

    Not in our library10.1016/j.stem.2008.11.009

12. 12.

    International Society for Stem Cell ResearchGuidelines for the clinical translation of stem cells[http://www.isscr.org/docs/guidelines/isscrglclinicaltrans.pdf]

    Not in our library

13. 13.

    Caulfield T Stem cell research and economic promisesJ Law Med Ethics2010 38303313

    Not in our library10.1111/j.1748-720x.2010.00490.x

14. 14.

    Caulfield T Rachul C Zarzeczny A The evolution of policy issues in stem cell research: an international surveyStem Cell Rev Rep2012 810371042

    Not in our library10.1007/s12015-012-9404-5

15. 15.

    Emanuel EJ Wendler D Grady C What makes clinical research ethical?JAMA2000 28327012711

    Not in our library10.1001/jama.283.20.2701

16. 16.

    Kato K Kimmelman J Robert J Sipp D Sugarman J Ethical and policy issues in the clinical translation of stem cells: report of a focus session at the ISSCR annual meetingCell Stem Cell2012 11765767

    Not in our library10.1016/j.stem.2012.11.004

17. 17.

    London AJ Kimmelman J Emborg ME Beyond access vs. protection in trials of innovative therapiesScience2010 328829830

    Not in our library10.1126/science.1189369

18. 18.

    King NM Cohen-Haguenauer O En route to ethical recommendations for gene transfer clinical trialsMol Ther2008 16432438

    Not in our library10.1038/mt.2008.13

19. 19.

    Dresser R First-in-human trial participants: not a vulnerable population, but vulnerable nonethelessJ Law Med Ethics2009 373850

    Not in our library10.1111/j.1748-720x.2009.00349.x

20. 20.

    Dresser R Stem cell research as innovation: expanding the ethical and policy conversationJ Law Med Ethics2010 38332341

    Not in our library10.1111/j.1748-720x.2010.00492.x

21. 21.

    Dresser R Alive and well: the research imperativeJ Law Med Ethics2012 40915921

    Not in our library10.1111/j.1748-720x.2012.00720.x

22. 22.

    Dresser R The ubiquity and utility of the therapeutic misconceptionSoc Philos Policy2002 19271294

    Not in our library10.1017/s0265052502192119

23. 23.

    King NM Henderson GE Churchill LR Davis AM Hull SC Nelson DK Parham-Vetter PC Rothschild BB Easter MM Wilfond BS Consent forms and the therapeutic misconception: the example of gene transfer researchIRB2005 271

    Not in our library

24. 24.

    Hyun I The bioethics of stem cell research and therapyJ Clin Invest2010 1207175

    Not in our library10.1172/jci40435

25. 25.

    Daley GQ The promise and perils of stem cell therapeuticsCell Stem Cell2012 10740749

    Not in our library10.1016/j.stem.2012.05.010

26. 26.

    Sugarman J Human stem cell ethics: beyond the embryoCell Stem Cell2008 2529533

    Not in our library10.1016/j.stem.2008.05.005

27. 27.

    Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and ResearchGuidance for industry: considerations for the design and conduct of early-phase clinical trials of cellular and gene therapy products (DRAFT)2013 [http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM359073.pdf]

    Not in our library

28. 28.

    Sipp D Direct-to-consumer stem cell marketing and regulatory responsesStem Cells Translational Med2013 2638640

    Not in our library10.5966/sctm.2013-0040

29. 29.

    Weissman I Stem cell therapies could change medicine if they get the chanceCell Stem Cell2012 10663665

    Not in our library10.1016/j.stem.2012.05.014

30. 30.

    Hyun I Hochedlinger K Jaenish R Yamanaka S New advances in iPS cell research do not obviate the need for human embryonic stem cellsCell Stem Cell2007 4367368

    Not in our library10.1016/j.stem.2007.09.006

31. 31.

    King NM Coughlin CN Atala A Pluripotent stem cells: the search for the ‘perfect’ sourceMinn J Law Sci Technol2011 12715730

    Not in our library

32. 32.

    Ishii T Pera RA Greely HT Ethical and legal issues arising in research on inducing human germ cells from pluripotent stem cellsCell Stem Cell2013 13145148

    Not in our library10.1016/j.stem.2013.07.005

33. 33.

    Cohen CB Renewing the Stuff of Life: Stem Cells, Ethics, and Public Policy2007 New York: Oxford University Press

    Not in our library

34. 34.

    Human Embryonic Stem Cell Research Advisory Committee, The National AcademiesFinal Report and 2010 Amendments to the National Academies’ Guidelines for Human Embryonic Stem Cell Research2010 Washington, DC: National Academies Press

    Not in our library

35. 35.

    Yamanaka S Induced pluripotent stem cells: past, present, and futureCell Stem Cell2012 10678684

    Not in our library10.1016/j.stem.2012.05.005

36. 36.

    Pera MF Stem cells: the dark side of induced pluripotencyNature2011 4714647

    Not in our library10.1038/471046a

37. 37.

    Obokata H Wakayama T Sasai Y Kojima K Vacanti MP Niwa H Yamato M Vacanti CA Stimulus-triggered fate conversion of somatic cells into pluripotencyNature2014 505641647

    Not in our library10.1038/nature12968

38. 38.

    Cyranoski D Acid bath offers easy path to stem cellsNature2014 505596

    Not in our library10.1038/505596a

39. 39.

    Cyranoski D Acid-bath stem-cell study under investigationNature2014 [http://www.nature.com/news/acid-bath-stem-cell-study-under-investigation-1.14738]

    Not in our library10.1038/505596a

40. 40.

    Kimmelman J Baylis F Glass KG Stem cell trials: lessons from gene transfer researchHastings Cent Rep2006 362326

    Not in our library10.1353/hcr.2006.0012

41. 41.

    Hyun I Allowing innovative stem cell based therapies outside of clinical trials: ethical and policy challengesJ Law Med Ethics2010 38277285

    Not in our library10.1111/j.1748-720x.2010.00488.x

42. 42.

    Wilson JM A history lesson for stem cellsScience2009 324727728

    Not in our library10.1126/science.1174935

43. 43.

    Bretzner F Gilbert F Baylis F Brownstone RM Target populations for first-in-human embryonic stem cell research in spinal cordsCell Stem Cell2011 8468475

    Not in our library10.1016/j.stem.2011.04.012

44. 44.

    Lukovic D Stojkovic M Moreno-Manzano V Bhattacharya SS Erceg S Perspectives and future directions of human pluripotent stem cell-based therapies: lessons from Geron’s clinical trial for spinal cord injuryStem Cells Dev2014 2314

    Not in our library10.1089/scd.2013.0266

45. 45.

    Illes J Reimer C Kwon BK Stem cell clinical trials for spinal cord injury: readiness, reluctance, redefinitionStem Cell Rev2011 79971005

    Not in our library10.1007/s12015-011-9259-1

46. 46.

    Esch MB King TL Shuler ML The role of body-on-a-chip devices in drug and toxicity studiesAnn Rev Biomed Eng2011 135572

    Not in our library10.1146/annurev-bioeng-071910-124629

47. 47.

    Lowenthal J Lipnick S Rao M Hull SC Specimen collection for induced pluripotent stem cell research: harmonizing the approach to informed consentStem Cells Translational Med2012 1409421

    Not in our library10.5966/sctm.2012-0029

48. 48.

    Lomax GP Hull SC Lowenthal J Rao M Isasi R The DISCUSS project: induced pluripotent stem cell lines from previously collected research biospecimens and informed consent: points to considerStem Cells Translational Med2013 2727730

    Not in our library10.5966/sctm.2013-0099

49. 49.

    Lomax GP Shepard KA Return of results in translational iPS cell research: considerations for donor informed consentStem Cell Res Ther2013 467

    Not in our library10.1186/scrt154

50. 50.

    Hyun I The bioethics of iPS cell based drug discoveryClin Pharmacol Ther2011 89646647

    Not in our library10.1038/clpt.2010.308

51. 51.

    King NM Coughlin CN Furth M Ethical issues in regenerative medicineWake Forest Intellectual Property Law J2009 9216238

    Not in our library

52. 52.

    Faden RR Dawson L Bateman-House AS Agnew DM Bok H Brock DW Chakravarti A Gao XJ Greene M Hansen JA King PA O’Brien SJ Sachs DH Schill KE Siegel A Solter D Suter SM Verfaillie CM Walters LB Gearhart JD Public stem cell banks: considerations of justice in stem cell research and therapyHastings Center Rep2003 331327

    Not in our library

53. 53.

    Caulfield T Rachul C Science spin: iPSC research in the newsClin Pharmacol Ther2011 89644646

    Not in our library10.1038/clpt.2010.309

Cited by papers we hold 4

• Adipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatment · 2025
  Not checked
• Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions · 2024
  No notice
• Adipose-Derived Stem Cells: Current Applications and Future Directions in the Regeneration of Multiple Tissues · 2020
  No notice
• Myelin damage and repair in pathologic CNS: challenges and prospects · 2015
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.